NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCTs031190014

Registered date:22/04/2019

Vaccination against measles and rubella for child treated with steroid

Basic Information

Recruitment status Complete
Health condition(s) or Problem(s) studiedDiseases requiring steroid treatments
Date of first enrollment01/05/2019
Target sample size40
Countries of recruitment
Study typeInterventional
Intervention(s)Measles and rubella vaccination for pediatric patients treated with steroid

Outcome(s)

Primary OutcomePositive sero-conversion rate of specific virus antibody after vaccination
Secondary OutcomeComparison of the specific virus antibody titer before and after vaccination

Key inclusion & exclusion criteria

Age minimum>= 5age old
Age maximum< 15age old
GenderBoth
Include criteria1. Aged from 5 years old to under 15 years old 2. Current treatment with steroids the dose of which satisfies all of the following 2-1.Less than 1mg/kg/day or 2mg/kg/day 2-2.Less than 20mg/day 2-3.No increase in steroids more than 4 weeks or 28 days 3. Patients of inoculation with MR vaccine once at a year old or over
Exclude criteria1. Current treatment with high dose immunosuppressive agents Definition of high dose immunosuppressive agents is as follows Salazosulfapyridine more than 40mg/kg/day Leflunomide more than 0.25mg/kg/day Methotrexate more than 15mg/m2/week Cyclosporine more than 2.5mg/kg/day Tacrolimus more than 0.06mg/kg/day Azathioprine more than 1mg/kg/day Cyclophosphamide more than 0.5mg/kg/day 6-Mercaptopurine more than 1.5mg/kg/day 2. Cases with side effect requiring treatment at the time of MR vaccination in the past 3. Cases with febrile disease within 4 weeks prior to vaccination 4. Cases receiving transfusion or administration of biological products within 3 months prior to vaccination 5. Cases receiving other live attenuated vaccine within 4 weeks or 28 days 6. Cases receiving inactivated vaccine within 6 days 7. Cases diagnosed as primary immunodeficiency disease 8. Cases likely to require treatment enhancement within 4 weeks after vaccination 9. Cases in whom both of measles and rubella antibody titers were higher than criteria 10. Cases living with a pregnant woman

Related Information

Contact

Public contact
Name Taku Ishii
Address Bunkyo-ku, Yushima, 1-5-45 Tokyo Japan 113-8519
Telephone +81-3-5803-5249
E-mail tishii.ped@tmd.ac.jp
Affiliation Tokyo Medical and Dental University Hospital of Medicine
Scientific contact
Name Taku Ishii
Address Bunkyo-ku, Yushima, 1-5-45 Tokyo Japan 113-8519
Telephone +81-3-5803-5249
E-mail tishii.ped@tmd.ac.jp
Affiliation Tokyo Medical and Dental University Hospital of Medicine